



03-20-02

#5 0300
BOX 566

EXPRESS MAIL CERTIFICATE

Date

3/18/02

Label No.

03914019318

I hereby certify that, on the date indicated above, this paper or fee was deposited with the U.S. Postal Service & that it was addressed for delivery to the U.S. Patent and Trademark Office, Box Sequence, P.O. Box 2327 Arlington, VA 22202 by "Express Mail Post Office to Addressee" service.

A. DiLullo A. DiLullo

Name (Print)

Signature

PLEASE CHARGE ANY DEFICIENCY UP TO \$300.00 OR CREDIT ANY EXCESS IN THE FEES DUE WITH THIS DOCUMENT TO OUR DEPOSIT ACCOUNT NO. 04-0100

Customer No.: 29311

Docket No: 2427/1F509-US1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Alessandra D'AZZO, et al.

Serial No.: 10/014,774

Confirmation No.: 9922

Filed: October 29, 2001

For: PROTEIN SPECIFIC FOR CARDIAC AND SKELETAL MUSCLE

**SUBMISSION OF SEQUENCE LISTING
AND
STATEMENT PURSUANT TO 37 C.F.R. § 1.821**

March 18, 2002

Hon. Commissioner of
Patents and Trademarks
Washington, DC 20231

Sir:

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures dated February 28, 2002, enclosed please find a computer readable form (diskette) and a paper copy containing the Sequence Listing pursuant to the requirements of 37 C.F.R. § 1.821-1.825.

Please enter the enclosed documents in the application file.

REMARKS

As stated in the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, the present application fails to comply with the sequence disclosure requirements set forth in 37 C.F.R. §1.821 through §1.825. Applicants are therefore requested to provide an initial Sequence Listing both as paper copy and as a computer readable form.

Pursuant to the requirements of 37 C.F.R. §1.821 through §1.825 for Sequence Listings, a computer readable form (diskette) and a paper copy containing the Sequence Listing are enclosed. Applicants note that the sequences contained in the enclosed Sequence Listing are disclosed, for example, at page 2, lines 22-24; page 8, lines 16-30; page 38, lines 31-32; page 39, lines 11-17, and Figures 2A, 2B, 3A, 3B, 4, and 6 of the specification as filed.

STATEMENT PURSUANT TO 37 C.F.R. § 1.821

Enclosed herewith is a computer readable form (diskette) and a paper copy containing sequence disclosure as requested by the Office. A copy of the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures is also enclosed. Pursuant to Rule 821, applicants herein state that the contents of the attached paper entitled "SEQUENCE LISTING" and of the accompanying identically labeled diskette, specifically

Serial No.: 10/014,774
Filed: October 29, 2001

the ASCII-encoded file therein labeled "seqlist.txt", are identical and that the submission contains no new matter.

CONCLUSION

Applicants request entry of the foregoing remarks in the file history of this application. Applicants respectfully submit that the application is now in compliance with the Sequence Listing Requirements pursuant to 37 C.F.R. §1.821 et seq. Substantive examination of the application is respectfully requested and a favorable determination respectfully solicited.

Respectfully submitted,



Irina E. Vainberg, Ph.D.
Registration No. 48,008
Agent for Applicants

DARBY & DARBY, P.C.
805 Third Avenue
New York, N.Y. 10022
Phone (212) 527-7700